Seoul Bio Hub , a bio-medical startup support platform operated by the Seoul Metropolitan Government, has begun recruiting participating companies for the '2025 Korea AstraZeneca-Seoul Bio Hub Global Open Innovation' program, which is being promoted jointly with the Korean branch of global pharmaceutical company AstraZeneca.
This program is a joint, open innovation program designed to help early-stage domestic bio and medical startups leverage the R&D expertise and international networks of global pharmaceutical companies to enhance their technological capabilities. The two organizations will provide customized support throughout the program, centered around the "AZ-SBH Joint Incubation Center," a joint incubation space established within the Seoul Bio Hub.
The program is open to bio- and medical-related startups established less than eight years ago. Applicants must fall within the therapeutic or technological areas identified by AstraZeneca. Therapeutic areas include oncology, cardiovascular, renal, and metabolic medicine, respiratory, immunology, and rare diseases, while technological areas include new drug target discovery, tissue-specific drug delivery, and sustainable biotechnology. The program provides broad support from preclinical to clinical trials.
Selected companies will receive a research grant of 35 million won per company and a one-year residency at the Seoul Bio Hub. These companies will also benefit from various startup support programs, including discounts on shared research equipment usage, investment, promotion, and networking programs, and participation in domestic and international exhibitions. AstraZeneca will also provide customized R&D mentoring from field experts, one-year rent support, and the opportunity to reside at the AstraZeneca Bio Venture Hub in Sweden.
Applications for participation can be submitted on the Seoul Bio Hub website until November 30th, and the final selection results will be individually announced in December.
- See more related articles
You must be logged in to post a comment.